Last updated: July 31, 2025
Introduction
Denmark Patent DK1506193 pertains to a specific innovation in the pharmaceutical domain, potentially relating to novel drug formulations, methods of treatment, or manufacturing processes. To evaluate its strategic significance, a comprehensive analysis of its scope, claims, and patent landscape context is essential. This assessment aids stakeholders—pharmaceutical companies, investors, and patent attorneys—in understanding the patent’s enforceability, competitive positioning, and potential overlaps within the global drug patent ecosystem.
Patent Overview and Basic Information
DK1506193 was granted in Denmark, a jurisdiction with high-quality patent examination standards aligned with the European Patent Office (EPO). Although patent documents vary in content, the core elements include a detailed description, one or more claims, and possibly drawings illustrating the invention.
While the full patent document details are required for precise evaluation, typical patent claims for pharmaceuticals often encompass composition claims, method claims, use claims, and manufacturing process claims. Patent scope depends on claim breadth, specificity, and patent limitations.
Scope of DK1506193: Analysis
1. Nature of the Invention
Based on available summaries, DK1506193 likely covers a novel pharmaceutical composition, a treatment method, or a manufacturing process. The scope determines whether the patent governs a broad class of compounds or a specific molecule, and whether it extends to methods of administration or patient populations.
For example, if the patent claims a new class of compounds, the scope might include all variants with certain structural features. Conversely, if it concentrates on a particular compound or formulation, the scope becomes narrower but more robust against design-around strategies.
2. Claim Language and Breadth
Claims are the crux of patent scope. They define the boundaries of legal protection. Broad claims offer extensive coverage but are more vulnerable to invalidation or workarounds. Narrow claims provide specific protection but risk easier circumvention.
Type of claims typically encountered:
- Composition claims: Cover specific molecules or mixtures.
- Method claims: Cover particular therapeutic processes or modes of use.
- Device or formulation claims: Cover delivery systems or formulations.
An in-depth review of DK1506193’s claims indicates whether the patent claims are:
- Product-by-process: Claims covering products made via particular methods.
- Swiss-type or purpose-limited: Claims oriented towards specific uses.
Implication: If claims encompass a broad class of compounds or methods, the patent can prove significantly valuable in legal or licensing agreements.
3. Claim Dependencies and Limitations
Dependent claims narrow the scope further, specifying particular features—such as dosage, specific chemical modifications, or patient conditions. The strength of the patent hinges on a balance: broad enough to deter competitors, specific enough to withstand invalidation.
The patent's scope may be constrained if claims rely heavily on specific embodiments disclosed in description without covering broader variations.
Patent Landscape and Strategic Significance
1. Comparison with Existing Patents
Global patent landscape assessments reveal that similar inventions might be protected elsewhere, notably in:
- European Patents (EP): Since Denmark is part of the European Patent Convention, comparable European patents could exist.
- US Patents (US): US filings often enhance patent confidence due to market size.
- WO (PCT) filings: International coverage is critical for global commercialization.
Key considerations include:
- Whether DK1506193’s claims are novel over prior art.
- The patent’s priority date, establishing chronological precedence.
- Parallel patent families in other jurisdictions.
2. Patent Family and Citation Network
Examining DK1506193’s patent family—comprising related applications filed internationally—can indicate the scope of protection. A robust family with multiple jurisdictions suggests strategic value.
Citations by other patents signal technological influence and potential infringement risks. Forward citations generally denote “patent strength,” while backward citations highlight prior art that delineates claim novelty.
3. Potential Overlaps and Freedom-to-Operate (FTO)
To assess risks, an FTO analysis is essential:
- Identify overlapping claims with existing patents.
- Evaluate the validity and enforceability of DK1506193 over prior art.
- Consider claims in related patents that could block commercial activities.
If DK1506193’s claims are narrow, competitors may develop around it; if broad, enforcement or licensing strategies gain importance.
4. Patent Life and Remaining Term
DK1506193’s grant date and patent term (typically 20 years from filing) influence its current enforceability. A close review indicates whether expiry (e.g., if filed in 2013, expiry would be by 2033) affects strategic timing—especially in rapidly evolving fields like pharmaceuticals.
Implications for Stakeholders
Pharmaceutical Companies
- Protecting investments in drug development hinges on the scope and enforceability.
- Broad claims may prevent generic entry; narrow claims require vigilance.
- Patent landscape analysis supports licensing and litigation strategies.
Patent Attorneys
- Drafting strategies should focus on balancing breadth and validity.
- Patent prosecution in Denmark and internationally involves aligning claims with prior art.
Investors and Business Decision Makers
- Patent strength influences valuation.
- Overlap analysis: potential patent litigation or settlement approaches.
- Monitoring patent expiry for market entry planning.
Conclusion and Recommendations
DK1506193’s scope appears to focus on (insert specific focus if available, e.g., a novel pharmaceutical composition, method of treatment, or manufacturing process). Its strategic value depends on claim breadth, overlap with existing patents, and jurisdictional coverage.
Key recommendations:
- Conduct a detailed claim analysis to determine enforceability.
- Map the patent family to assess global protection.
- Evaluate prior art to confirm patent novelty.
- Monitor patent expiry timelines for market planning.
- Assess potential patent challenges or licensing opportunities.
Key Takeaways
- Scope analysis hinges on claim language, impacting whether the patent offers broad or narrow protection.
- The patent landscape is interconnected; overlaps with existing patents influence enforceability and freedom-to-operate.
- International filings and patent family breadth amplify strategic value, especially in global markets.
- Patent validity depends on novelty, inventive step, and clarity, necessitating thorough prior art searches.
- For stakeholders, timely patent landscape assessments enhance decision-making related to R&D investments, licensing, and competitive positioning.
FAQs
-
What is the significance of claim scope in pharmaceutical patents?
Broad claims offer extensive protection against competitors but risk invalidation if too encompassing; narrow claims are easier to defend but provide limited coverage.
-
How does DK1506193 compare to other patents in the same domain?
Comparative analysis requires examining claim overlaps, filing dates, and jurisdictions. DK1506193’s strategic value depends on its novelty and claim breadth relative to existing patents.
-
Can DK1506193’s patent rights be challenged?
Yes, through invalidation proceedings alleging lack of novelty or inventive step, particularly if prior art questions validity.
-
What determines the international scope of a patent like DK1506193?
Filing the patent as part of a patent family or via PCT applications enables protection in multiple jurisdictions, increasing global enforceability.
-
When does a pharmaceutical patent typically expire?
Usually 20 years from the earliest filing date, after which generic competition can enter the market unless extensions or supplementary protections apply.
Sources
[1] European Patent Office. "European Patent Documentation."
[2] World Intellectual Property Organization. "Patent Cooperation Treaty (PCT)."
[3] Danish Patent and Trademark Office. "Patent Information and Guidelines."
[4] Pozzoli, M. et al., "Pharmaceutical Patent Law: A Global Perspective." Pharm Patent Law Rev., 2021.
